Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells

Journal of Clinical Oncology

Volumn 21, Issue 21, 2003, Pages 4016-4026

  Slingluff Jr , Craig L ^a   Petroni, Gina R ^a   Yamshchikov, Galina V ^a   Barnd, Donna L ^a   Eastham, Shannon ^a   Galavotti, Holly ^a   Patterson, James W ^a   Deacon, Donna H ^a   Hibbitts, Sarah ^a   Teates, David ^a   Neese, Patrice Y ^a   Grosh, William W ^a   Chianese Bullock, Kimberly A ^a   Woodson, Elizabeth M H ^a   Wiernasz, Catherine J ^a   Merrill, Priscilla ^a   Gibson, Jennifer ^a   Ross, Maureen ^a   Engelhard, Victor H ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; MELANOMA VACCINE; MONTANIDE ISA 51; SYNTHETIC PEPTIDE; TETANUS HELPER PEPTIDE; TYROSINASE PEPTIDE; UNCLASSIFIED DRUG; CANCER VACCINE; DRUG DERIVATIVE; MANNITOL; MELANOCYTE LINEAGE SPECIFIC ANTIGEN GP100; MELANOCYTE LINEAGE-SPECIFIC ANTIGEN GP100; MEMBRANE PROTEIN; MONOPHENOL MONOOXYGENASE; OLEIC ACID; PEPTIDE FRAGMENT; TUMOR PROTEIN;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HELPER CELL; HUMAN; IMMUNE RESPONSE; MELANOMA; PERIPHERAL LYMPHOCYTE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; ADULT; AGED; DRUG ADMINISTRATION; FEMALE; IMMUNOLOGY; LYMPH NODE; MALE; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; RADIOGRAPHY; SKIN TUMOR; SURVIVAL; THORAX TUMOR; TREATMENT OUTCOME;

ADULT; AGED; CANCER VACCINES; DENDRITIC CELLS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-2; LYMPH NODES; MALE; MANNITOL; MELANOMA; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MONOPHENOL MONOOXYGENASE; NEOPLASM PROTEINS; OLEIC ACIDS; PEPTIDE FRAGMENTS; SKIN NEOPLASMS; SURVIVAL ANALYSIS; T-LYMPHOCYTES; THORACIC NEOPLASMS; TREATMENT OUTCOME;

EID: 0642311904     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.10.005     Document Type: Article

References (30)

1. Slingluff CL Jr: Tumor antigens and tumor vaccines: Peptides as immunogens. Semin Surg Oncol 12:446-453, 1996
2. Dranoff G, Jaffee E, Lazenby A, et al: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 90:3539-3543, 1993
3. Soiffer R, Lynch T, Mihm M, et al: Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A 95:13141-13146, 1998
4. Jager E, Ringhoffer M, Arand M, et al: Cytolytic T cell reactivity against melanoma-associated differentiation antigens in peripheral blood of melanoma patients and healthy individuals. Melanoma Res 6:419-425, 1996
5. Scheibenbogen C, Schmittel A, Keilholz U, et al: Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J Immunother 23:275-281, 2000 [erratum p 509]
6. Ahlers JD, Dunlop N, Alling DW, et al: Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: Granulocyte- macrophage colony-stimulating factor and TNF-alpha synergize with IL-12 to enhance induction of cytotoxic T lymphocytes. J Immunol 158: 3947-3958, 1997
7. Kittlesen DJ, Thompson LW, Gulden PH, et al: Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: Implications for tumor vaccine development. J Immunol 160:2099-2106, 1998
8. [erratum in J Immunol 162:3106, 1999]
9. Skipper JC, Hendrickson RC, Gulden PH, et al: An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med 183:527-534, 1996
10. Cox AL, Skipper J, Chen Y, et al: Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264:716-719, 1994
11. Blum-Tirouvanziam U, Beghdadi-Rais C, Roggero MA, et al: Elicitation of specific cytotoxic T cells by immunization with malaria soluble synthetic polypeptides. J Immunol 153:4134-4141, 1994
12. Skipper JC, Kittlesen DJ, Hendrickson RC, et al: Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100. J Immunol 157:5027-5033, 1996
13. Kawakani Y, Robbins PF, Wang X, et al: Identification of new melanoma epitopes on melansomal proteins recognized by tumor infiltrating lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. J Immunol 161:6985-6992, 1998
14. Valmori D, Pessi A, Bianchi E, et al: Use of human universally antigenic tetanus toxin T cell epitopes as carriers for human vaccination. J Immunol 149:717-721, 1992
15. Slingluff CL Jr, Yamshchikov G, Neese P, et al: Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: Immunologic and clinical outcomes. Clin Cancer Res 7:3012-3024, 2001
16. Demotz S: Delineation of several DR-restricted tetanus toxin T cell epitopes. J Immunol 142:394-402, 1989
17. Yamshchikov GV, Barnd DL, Eastham S, et al: Evaluation of peptide vaccine immunogenicity in draining lymph nodes and blood of melanoma patients. Int J Cancer 92:703-711, 2001
18. Henderson RA, Michel H, Sakaguchi K, et al: HLA-A2.1-associated peptides from a mutant cell line: A second pathway of antigen presentation. Science 255:1264-1266, 1992
19. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
20. Tsuchida Y, Therasse P: Response evaluation criteria in solid tumors (RECIST): New guidelines. Med Pediatr Oncol 37:1-3, 2001
21. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
22. Dhodapkar MV, Steinman RM, Krasovsky J, et al: Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 193:233-238
23. Mayordomo JI, Zorina T, Storkus WJ, et al: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic amitumour immunity. Nat Med 1:1297-1302, 1995
24. Nair SK, Snyder D, Rouse BT, et al: Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer 70:706-715, 1997
25. Nestle FO, Alijagic S, Gilliet M, et al: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328-332, 1998
26. Koch F, Heufler C, Kampgen E, et al: Tumor necrosis factor alpha maintains the viability of murine epidermal Langerhans cells in culture, but in contrast to granulocyte/macrophage colony-stimulating factor, without inducing their functional maturation. J Exp Med 171:159-171, 1990
27. Heufler C, Koch F, Schuler G: Granulocyte/macrophage colony-stimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells. J Exp Med 167:700-705, 1988
28. Ahmed FY, Leonard GA, A'Hern R, et al: A randomised dose escalation study of subcutaneous interleukin-2 with or without levamisole in patients with metastatic renal cell carcinoma or malignant melanoma. Br J Cancer 74:1109-1113, 1996
29. Schomburg A, Menzel T, Korfer A, et al: In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant interleukin-2. Nat Immunol 11:133-143, 1992
30. Farace F, Angevin E, Dietrich, P-Y, et al: Low-dose IL-2 treatment: Activation of discrete T- and NK-cell sub-populations in vivo. Int J Cancer 62:523-528, 1995